IRIS
SVEGLIATI BARONI, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.331
EU - Europa 3.547
AS - Asia 2.550
SA - Sud America 758
Continente sconosciuto - Info sul continente non disponibili 139
AF - Africa 134
OC - Oceania 6
AN - Antartide 1
Totale 12.466
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.210
RU - Federazione Russa 1.119
SG - Singapore 774
BR - Brasile 594
VN - Vietnam 584
CN - Cina 446
IT - Italia 434
UA - Ucraina 430
DE - Germania 299
SE - Svezia 292
IE - Irlanda 241
TR - Turchia 212
HK - Hong Kong 200
FR - Francia 185
DK - Danimarca 155
FI - Finlandia 135
GB - Regno Unito 108
KR - Corea 87
CA - Canada 65
AR - Argentina 55
IN - India 52
BD - Bangladesh 33
ZA - Sudafrica 33
CI - Costa d'Avorio 32
EC - Ecuador 32
PL - Polonia 32
MA - Marocco 28
MX - Messico 27
ID - Indonesia 25
CO - Colombia 22
IQ - Iraq 21
ES - Italia 19
NL - Olanda 19
AT - Austria 18
BE - Belgio 18
PK - Pakistan 18
JP - Giappone 15
VE - Venezuela 15
TN - Tunisia 13
LT - Lituania 12
PY - Paraguay 12
CL - Cile 11
EG - Egitto 8
SA - Arabia Saudita 8
UY - Uruguay 8
UZ - Uzbekistan 8
CR - Costa Rica 7
AU - Australia 6
EU - Europa 6
JO - Giordania 6
KZ - Kazakistan 6
MY - Malesia 6
OM - Oman 6
PH - Filippine 6
DZ - Algeria 5
NP - Nepal 5
PS - Palestinian Territory 5
RS - Serbia 5
HN - Honduras 4
JM - Giamaica 4
LB - Libano 4
PE - Perù 4
SN - Senegal 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GE - Georgia 3
IL - Israele 3
KE - Kenya 3
MD - Moldavia 3
NI - Nicaragua 3
TW - Taiwan 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
CZ - Repubblica Ceca 2
GA - Gabon 2
HR - Croazia 2
PT - Portogallo 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
SV - El Salvador 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AQ - Antartide 1
BH - Bahrain 1
CG - Congo 1
CH - Svizzera 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
Totale 12.326
Salva come PNG Salva come JPEG
Città #
Ashburn 699
Chandler 605
Singapore 451
Jacksonville 434
San Jose 244
Boardman 239
Dublin 237
Council Bluffs 233
Ho Chi Minh City 207
Dallas 194
Hong Kong 193
Fairfield 183
New York 159
Beijing 149
Wilmington 140
Hanoi 122
The Dalles 116
Lawrence 93
Princeton 93
Centro 87
Los Angeles 87
San Mateo 87
Woodbridge 86
Moscow 85
Des Moines 81
Lauterbourg 81
Ann Arbor 79
Houston 78
São Paulo 67
Munich 61
Seattle 60
Hefei 55
Milan 51
Ancona 49
Cambridge 49
Buffalo 45
Da Nang 39
Helsinki 36
San Diego 33
Turin 32
Abidjan 31
Orem 30
London 29
Warsaw 27
Santa Clara 24
Nuremberg 21
Turku 21
Haiphong 20
Montreal 20
Phoenix 20
Rio de Janeiro 20
Chicago 19
Chennai 17
Johannesburg 17
Brussels 16
Guangzhou 15
San Francisco 15
Shanghai 14
Stockholm 14
Denver 13
Frankfurt am Main 13
Poplar 13
Washington 13
Atlanta 12
Belo Horizonte 11
Boston 11
Guayaquil 11
Izmir 11
Marche 11
Mexico City 11
Pune 11
Toronto 11
Brooklyn 10
Goiânia 10
Porto Alegre 9
Rome 9
Tokyo 9
Wuhan 9
Amsterdam 8
Brasília 8
Bắc Ninh 8
Curitiba 8
Guarulhos 8
Hải Dương 8
Juneau 8
Miano 8
Monte San Pietrangeli 8
Montevideo 8
Redmond 8
Ankara 7
Buenos Aires 7
Charlotte 7
Tashkent 7
Amman 6
Biên Hòa 6
Bắc Giang 6
Caxias do Sul 6
Columbus 6
Itaquaquecetuba 6
Jesi 6
Totale 6.875
Salva come PNG Salva come JPEG
Nome #
ALTERATIONS OF ROS PATHWAYS IN SCLERODERMA BEGIN AT STEM CELL LEVEL 816
Characterization of binding and quantification of human autoantibodies to PDGFRα using a biosensor-based approach 193
Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti−Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies 192
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 188
Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients 185
Metabolomic profile of systemic sclerosis patients 181
c-MYB transactivates the alpha 2(I) collagen gene. 167
Agonistic anti-PDGF receptor autoantibodies from patients with systemic sclerosis impact human pulmonary artery smooth muscle cells function in vitro 161
Epitope specificity determines pathogenicity and detectability of anti-platelet-derived growth factor receptor α autoantibodies in systemic sclerosis 161
Activation in vitro of scleroderma skin fibroblasts is sustained by increased generation of free radicals through the NADPH-oxidase pathway. 156
A reactive Oxygen species -mediated loop mantains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis 156
Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality 155
B CELL RECEPTOR EDITING IN SCLERODERMA PATIENTS GENERATES PATHOGENIC ANTI-PDGFR AUTOANTIBODIES 154
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease 153
Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease 151
Long lasting biological effects of PDGFR agonistic auto-antibodies in scleroderma 150
Bone formation by distraction clinical and structural studies 150
Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice 150
The Exaggerated Collagen Expression in Gvhd-Fibroblasts Is Effectively Inhibited By Therapeutic Concentration of Nilotinib 143
Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK 1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts 136
DETECTION OF STIMULATORY ANTI-PDGF RECEPTOR AUTOANTIBODIES BY BIOASSAYS BASED ON DIFFERENT CELL LINES 136
AUTOIMMUNITY TO PDGFR: A RELEVANT PATHOGENIC LINK IN SSc 134
Agonistic antibodies in systemic sclerosis 133
PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis 133
Ha-Ras/ERK1-2 pathway is responsable for oxygen species generation by scleroderma skin fibroblasts 132
Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches 132
Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis 131
Isolation of agonistic autoantibodies specific for the PDGF receptor from the B cell repertoire of SSC patients 130
The long pentraxin PTX3 is a marker of scleroderma fibroblasts activation 129
Cloning of agonistic autoantibodies specific for the PDGF receptor from the B-cell repertoire of SSc patients 128
Characterization of the c-Myb-responsive region and regulation of the human type I collagen α2 chain gene by c-Myb 127
Mechanism of action of agonistic PDGFR auto-antibodies isolated from scleroderma patients 127
CLONING OF AGONISTIC AUTOANTIBODIES SPECIFIC FOR THE PDGF RECEPTOR FROM THE B CELL REPERTOIRE OF PATIENTSAFFECTED BY SYSTEMIC SCLEROSIS 127
Pathogenic autoantibodies in systemic sclerosis 126
Patients with chronic extensive GvHD produce high levels of stimulatory auto-antibodies to the PDGF receptor: a new pathophysiological pathway of the disease progression 126
Dietary restriction affects antioxidant levels in rat liver mitochondria during ageing 125
Stimulatory autoantibodies against PDGF receptors in Scleroderma 125
Intracellular free radical production by peripheral blood T lymphocytes from patients with systemic sclerosis: Role of NADPH oxidase and ERK1/2 125
Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis 124
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 124
The Wnt signalling inhibitor gene, WIF1, is silenced in fibroblasts derived from Systemic Sclerosis patients: role of oxidative stress 123
Autoantibodies against the platelet-derived growth factor receptor in scleroderma: comment on the articles by Classen et al and Loizos et al. 122
Stimulatory autoantibodies against PDGF receptor in serum from patients with GVHD and scleroderma-like changes 121
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients 121
Association between TNF-α, cortisol levels, and exposure to PM10 and PM2.5: a pilot study 120
NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis 120
Adeno-associated virus type 5 infection via PDGFRα is associated with Interstitial lung disease in systemic sclerosis and generates composite peptides and epitopes recognized by the agonistic immunoglobulins present in patients with systemic sclerosis 119
WIF1, A WNT PATHWAY INHIBITOR, IS SILENCED IN SYSTEMIC SCLEROSIS BY DNA DAMAGE: A MECHANISM LINKING DNA DAMAGE TO WNT AND FIBROSIS 119
Ha-Ras/ERK1-2 pathway is responsible for oxygen species generation in scleroderma fibroblasts 119
Coenzyme Q homologs and vitamin E in synaptic and non-synaptic occipital cerebral cortex mitochondria in the ageing rat. 117
Putative functional pathogenic autoantibodies in systemic sclerosis 117
Stimulating autoantibodies to PDGF A/B receptor on sera from scleroderma patients 115
Stimulatory autoantibodies against PDGF receptor in systemic sclerosis 114
Solid monounsaturated diet lowers LDL unsaturation trait and oxidisability in hypercholesterolemic (type IIb) patients 114
Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvemen 114
Oxidative DNA damage induces the ATM-mediated transcriptional suppressionof the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis 113
Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. 110
Tissue-targeted antifibrotic gene therapy using a transgene driven by the promoter of the human type I collagen gene 110
Isolation and cloning of stimulatory anti-PDGF receptor auto-antibodies from the immunological repertoire of patients with systemic sclerosis 110
Isolation and cloning of stimulatory anti-PDGF receptor auto-antibodies from the immunological repertoire of patients with systemic sclerosis 110
Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab 110
Dietary restriction affects antioxidant levels in rat liver mitochondria diuring aging 109
Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis 109
Scleroderma-like fibrosis in chronic graft-vs-host disease is sustained by anti-PDGF receptors antibodies 108
Scleroderma fibroblasts constitutively express the long pentraxin PTX3. 108
PDGF receptor as therapeutic and diagnostic target in systemic sclerosis 108
Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets 108
Coenzyme Q homologs and Vitamin E in synaptic and non-synaptic occipital cerebral cortex mitochondria in the aging rat 107
Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts 107
H-Ras but not K-Ras is responsible for reactive oxygen species generation by scleroderma skin fibroblasts. 107
Stimulatory auto-antibodies to the PDGF receptor in patients with chronic GVHD. 105
Oxidative stress in scleroderma - Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway 103
Monounsaturated diet lowers LDL oxidisability in type IIb and type IV dyslipidemia without affecting coenzyme Q10 and vitamin E contents 103
Biological effects of serum immunoglobulins from scleroderma patients on human pulmonary artery smooth muscle cells. Role of NOX4 and ROS 102
The Wnt signalling inhibitor gene, WIF-1, expression is downregulated in fibroblasts derived from systemic sclerosis patients by a persistent oxidative stress 101
Development of a Skin-Humanized Model as a Novel Tool to Investigate the Pathogenesis of Scleroderma 99
Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine 99
The treatment of UCD200 and scleroderma fibroblasts with siRNAs anti-C-MYB blocks type I collagen transcription: Toward a gene therapy of scleroderma 98
Stimulatory Auto-Antibodies To The PDGF Receptor As Pathology Marker And Therapeutic Target 97
Rituximab for the treatment of cutaneous involvement in systemic sclerosis. evidence for a pathogenetic role of B-CELLS 97
Lipid raft colocalization of PDGFR-NADPH complex and receptor integrity are important for the activation of the intracellular signaling by scleroderma IgG in normal human fibroblasts 94
Isolation of agonistic autoantibodies specific for the PDGF receptor from the B cell repertoire of SSC patients 93
Stimulatory autoantibodies against PDGF receptor in serum from patients with GVHD and scleroderma-like changes. 92
Unbalance between Ha- and Ki-Ras is responsible for scleroderma fibroblast activation 92
The important role of molecular analyses to evaluate the efficacy of Rituximab treatment in a patient affected by severe multineuropathy in mixed cryoglobulinemia disease. 91
STIMULATORY AUTOANTIBODIES AGAINST PDGF RECEPTOR IN A LARGE COHORT OF ITALIAN SCLERODERMA PATIENTS 91
Reactive oxygen species are required for manteinance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. 89
Epitopes of the human PDGF receptor able to bind human auto-antibodies, antibodies and uses thereof 88
Screening and Analysis of Possible Drugs Binding to PDGFRα: A Molecular Modeling Study 87
Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of free radical generation through the NADPH oxidase complex pathway 87
Intracellular free radical production by peripheral blood T lymphocytes from patients with Systemic Sclerosis: role of NADPH oxidase and ras 85
Stimulatory autoantibodies to the PDGF receptor in scleroderma (Correspondence) 82
Restricted immunoglobulin repertoire and evolutionary mechanism of PDGFR-autoreactive memory B cells in systemic sclerosis 82
Monounsaturated diet lowers LDL oxidisability in type IIb and type IV dyslipidemia without affecting coenzyme Q10 and vitamin E contents 81
Restricted immunoglobulin repertoire and evolutionary mechanism of PDGFR-autoreactive memory B cells in systemic sclerosis 78
New insights into the role of oxidative stress in scleroderma fibrosis. 70
Expression profile and regulation of NOX proteins in Systemic Sclerosis 63
Dietary olive oil affects LDL peroxidability in hypercholesterolemic (IIB) patients 62
Exploring potential VEGF receptor 2 inhibitors: a molecular modeling and pharmacophore-based screening approach 34
Micro- and Macro-Vascular Disease in Systemic Sclerosis and Very Early SSc (VEDOSS): Results from a Monocentric Observational Study 23
Totale 12.449
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.092
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.092
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022409 0 0 9 32 11 24 14 56 42 32 51 138
2022/20231.530 134 188 110 161 138 202 6 98 366 9 82 36
2023/2024752 140 29 40 125 127 170 9 12 0 15 6 79
2024/20251.553 149 145 68 12 93 18 174 43 353 103 168 227
2025/20265.121 379 491 235 502 467 349 677 450 958 306 119 188
2026/2027449 158 155 136 0 0 0 0 0 0 0 0 0
Totale 12.466